If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
88
results.
Updated on
09/05/2025 [07:16:00]
Results 50 to 75 of 88
Absstract of: CN119530098A
The invention discloses a lactobacillus bornicaule NM3 and application thereof, and belongs to the field of microorganisms. The lactobacillus pocortisone NM3 is preserved in the Guangdong Microbiological Culture Collection Center, and the preservation number is GDMCC NO: 65604. The strain is screened from intestinal tracts of spotted-brown chickens, is good in source safety, has a good inhibition effect on pathogenic bacteria including salmonella pullorum, escherichia coli and the like, has good application potential in the aspect of preventing and treating the pathogenic bacteria, is wide in prospect, can be used for preparing products for preventing and treating the pathogenic bacteria, and has wide application prospects. The strain is a probiotic strain worthy of development.
Absstract of: WO2025039454A1
A breast milk-derived Limosilactobacillus fermentum MSJK0025 capable of improving the intestinal flora condition and the use thereof. The breast milk-derived Limosilactobacillus fermentum MSJK0025 is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No. 26426. The breast milk-derived Limosilactobacillus fermentum is a new strain isolated from breast milk of healthy puerperae, and is referred to as Limosilactobacillus fermentum MSJK0025. The strain has a good antibiotic sensitivity and stable inheritance of traits, has a good tolerance to acid, bile salts and artificial gastric/intestinal fluid, and has a fast growth rate and good safety. Furthermore, the strain has a strong intestinal colonization capability and can effectively inhibit intestinal pathogenic bacteria such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and Candida albicans, but has no inhibitory effects on intestinal probiotics such as Lactobacillus and Bifidobacterium.
Absstract of: WO2025042889A1
The present disclosure provides formulations, kits, and vaccines directed to immunization of animals against Salmonella. Methods of usng the formulations, kits, and vaccines for protection of avians against one or more species of Salmonella are also provided.
Absstract of: US2025066429A1
The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.
Absstract of: US2025064866A1
The present invention relates to the field of cancer therapy. In particular, the present invention relates to a first composition comprising a live attenuated bacterium for use in the treatment, prevention, reduction, inhibition, prevention of recurrence, or control of a neoplastic disease in a subject being or intended to be administered a second composition comprising a live attenuated bacterium, said bacterium being the same or different to that of the first composition and methods thereof.
Absstract of: US2025064910A1
Technologies for the prevention and/or treatment of Salmonella infections.
Absstract of: EP4512482A2
The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being:- devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and- substituted at position C6' of the non-reducing end of their lipid A domain by a hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group.It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject.
Absstract of: CN119506141A
The invention discloses a strain of Shenjing pig combined lactobacillus and application thereof. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.31452. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age and is sensitive to various common antibiotics, and fermented supernate of the strain shows relatively strong inhibition capability on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, salmonella paratyphi B and gardnerella vaginalis; the compound has strong adhesion ability, growth inhibition ability and apoptosis promoting effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of amino acid and bioactive substances such as peptides, arachidonic acids, steroids and polyketones can be greatly increased, the strain has an obvious inhibition effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in biological agents, but also opens up a new way for combined application of lactic acid bacteria and ganoderma spores.
Absstract of: CN119506142A
The invention discloses a lactobacillus jensenii strain and application thereof in fermentation of wall-broken ganoderma lucidum spore powder. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.31484. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age, is sensitive to various common antibiotics, and has strong lactic acid production capacity; a fermentation supernatant of the bacillus subtilis shows relatively strong inhibition capability on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, shigella dysenteriae, yersinia enterocolitica and gardnerella vaginalis, and has relatively strong adhesion capability, growth inhibition capability and apoptosis promotion effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of amino acid and bioactive substances such as peptides, arachidonic acids, steroids and polyketones can be greatly increased, the strain has an obvious inhibition effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in biological agents, but also opens up a new way for combined application of lactic acid bacteria and ganoderma spores.
Absstract of: CN119506449A
The invention provides an SLAMP primer group and a kit for detecting salmonella, and relates to the technical field of biological detection. The SLAMP primer group is a primer group aiming at the amplification of a conserved region fragment of salmonella, and is a primer pair SAL-SF/SAL-SR; wherein the nucleotide sequence of the SAL-SF is as shown in SEQ ID NO. 1, and the nucleotide sequence of the SAL-SR is as shown in SEQ ID NO. 2. According to the method or the kit provided by the invention, the salmonella can be rapidly and accurately detected without expensive instruments or complicated operation, so that the method or the kit is suitable for on-site rapid detection of ports, communities and the like with low professional degree. According to the visual kit provided by the invention, great convenience is provided for field detection, and rapid and accurate non-diagnostic purpose detection of salmonella can be realized.
Absstract of: CN119506315A
The invention discloses a recombinant salmonella choleraesuis nuclease regulation vector as well as a construction method and application thereof. After oral administration, the recombinant salmonella choleraesuis nuclease regulatory vector rSC0140 enters host immune cells, c-di-AMP is released, a host STING pathway is activated, and a broad-spectrum antiviral effect can be achieved; the recombinant strain rSC0140 is proved to be capable of activating STING pathways in macrophages and mice, causing antiviral states of the macrophages and the mice and resisting challenge of various influenza viruses; the recombinant strain has broad-spectrum antiviral efficacy and is suitable for preventing and treating various virus diseases clinically.
Absstract of: CN119506144A
The invention provides a combined lactobacillus salivarius strain 8-2 and an application of the combined lactobacillus salivarius strain 8-2. The combined lactobacillus salivarius strain 8-2 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the combined lactobacillus salivarius strain 8-2 is CGMCC NO.30612. The invention further provides a preparation method of the combined lactobacillus salivarius strain 8-2. The lactobacillus salivarius disclosed by the invention has the advantages of good acid resistance, no hemolysis and relatively strong antibacterial ability, can relieve injury caused by salmonella infection, can effectively promote the absorption function of intestinal mucosa, improves the production performance of laying hens, and improves the production efficiency of the laying hens. The strain has the potential of being developed into a laying hen high-quality probiotic preparation with an anti-replacement function and a function of promoting intestinal mucosal injury repair, and can be applied to preparation of laying hen antibiotic substitutes, including application of strain fermentation supernatant in preparation of laying hen antibiotic substitutes.
Absstract of: CN119504470A
The invention relates to the technical field of compound eutectic crystals, and discloses an L-carnitine and plant essential oil active component eutectic crystal and a preparation method and application thereof. The eutectic crystal is prepared from the following raw materials: L-carnitine and plant essential oil active ingredients, the molar ratio of the L-carnitine to the active ingredients of the plant essential oil is 1: 1; the plant essential oil active component is selected from at least one of thymol and carvacrol. The eutectic crystal provided by the invention is formed by at least one of thymol and carvacrol and L-carnitine, is low in hygroscopicity and volatility and good in stability, and overcomes the defects that single L-carnitine is strong in hygroscopicity and inconvenient to process and store, and single thymol or carvacrol is strong in volatility and poor in stability; compared with single thymol or carvacrol, the eutectic crystal shows lower minimum inhibitory concentration on escherichia coli, candida albicans, salmonella enteritidis, aspergillus niger and the like, and has a good antibacterial effect.
Absstract of: CN119506446A
The invention discloses a nucleic acid detection kit for typhoid fever, paratyphoid fever, cholera, shigella and dysentery. The nucleic acid detection kit comprises a multiple fluorescent PCR detection system, and the multiple fluorescent PCR detection system comprises a typhoid fever salmonella primer probe, a paratyphoid fever salmonella primer probe, a vibrio cholera primer probe, a dysentery amoeba primer probe and a shigella primer probe; according to the kit, specific and conservative characteristic genes of different bacteria species are selected for primer probe design, so that the specificity, the accuracy and the sensitivity of detection are ensured.
Absstract of: CN119491012A
本发明公开了一种重组鼠伤寒沙门氏菌的构建方法及其产品和应用，本发明中rSC0134(pS‑PlcC‑NetB)在免疫初期能够刺激机体产生充分的免疫应答，在免疫后期呈现出程序性的自我清除，具有一定安全性；rSC0134(pS‑PlcC‑NetB)免疫肉鸡后可产生强大的体液免疫，黏膜免疫和细胞免疫，保护肉鸡免受坏死性肠炎的感染；本发明构建了一种重组减毒鼠伤寒沙门氏菌疫苗载体平台，为开发针对鸡源传染病疫苗的递送平台提供了一种有前景的策略，具有较大的市场应用潜力和潜在的经济效益。
Absstract of: AU2025200704A1
Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion ofpagP or modification ofpagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin" and/orpagP'. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine and/or purine auxotrophs. The bacteria optionally are one or more of asct, purl'and msbB'. The immunostimulatory bacteria, such as Salmonella species, are modified to encode proteins that induce type I interferon (IFN) expression, or that are variants thereof that have increased activity to induce type I IFN expression, or that are variants thereof that result in constitutive expression of type I IFN. The bacteria can encode a modified Stimulator of Interferon Genes (STING) protein from a non-human species, that has lower NF-KB signaling activity, and, optionally, higher type I IFN pathway signaling activity, compared to human STING. The bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the
Absstract of: WO2025037284A2
A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.
Absstract of: US2021077605A1
The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one further anti-cancer agent. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, wherein the pharmaceutical composition further comprises at least one further attenuated strain of Salmonella comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen or a tumor stroma antigen.
Absstract of: CN119464526A
The invention relates to the field of microbiological detection, in particular to a method for simultaneously and rapidly detecting at least two target objects, which comprises the following steps: S101, obtaining a first mixture; s102, obtaining a second mixture; s103, centrifuging the first mixture, collecting a first supernatant, centrifuging the second mixture, and collecting a second supernatant; s104, obtaining a third mixture; and S105, analyzing the existence and/or concentration of the first target object and/or the second target object in the sample to be detected according to the fluorescence intensity signal. The method has high detection sensitivity, good specificity, reproducibility, stability and anti-interference performance, and realizes enzyme-free, DNA-free, ultra-sensitive and wide-linear-range double-target detection.
Absstract of: CN119464523A
The invention relates to the technical field of salmonella detection, and provides a photonic crystal fluorescence sensor based on recombinase polymerase amplification and a CRISPR/Cas12a system, and the photonic crystal fluorescence sensor comprises a biosensing platform and a photonic crystal array; the reaction components of the biosensing platform comprise an RPA reagent, an upstream primer, a downstream primer, Cas12a protein, crRNA, an ssDNA probe and a buffer solution; the photonic crystal array is mainly constructed by a PDMS substrate, polystyrene microspheres, ethanol and a microwell plate analyzer; the detection sensitivity of the salmonella is obviously improved.
Absstract of: CN119470891A
本发明涉及一种基于MIL(53)‑Fe纳米酶活性的细菌检测方法。本发明的细菌检测方法通过将适配体与铁基金属有机骨架结合形成细菌探针，并利用MIL(53)‑Fe在过氧化氢存在的条件下将TMB催化生成TMB+的性能，同时将生成的TMB+酸化形成TMB2+，利用TMB2+对金纳米棒的蚀刻导致金纳米棒颜色发生变化，进而实现细菌的检测。该检测方法简单快捷，且对金黄色葡萄球菌的最低检测限为1.16CFU/mL，大肠杆菌的最低检测限为1.02CFU/mL，具有广阔的应用前景。除此以外，本发明的检测结果肉眼可见，可作为定性检测的依据。
Absstract of: CN119464306A
本发明提供一种装载肉桂醛的固液双相人工细胞(SL‑BACs)，其具有固相保护膜和液态多核，其利用微流体T型芯片，高效、稳定地制造获得。SL‑BACs可对鼠伤寒沙门氏菌诱发的结肠炎提供多方面治疗帮助，首先液态多核内的适配体在感染部位表现出精准靶向性；其次，SL‑BACs对肉桂醛的包封率较高，约为82.9％；再次，膜结构将SL‑BACs的肠道保留时间延长至15h；并且SL‑BACs表现出pH响应性，控制释放液态多核抗菌，其杀菌率为95.28％。SL‑BACs还能降低促炎细胞因子分泌，优化肠道微生物群组成，维持肠道稳态。总之，SL‑BACs为将人工细胞模块化成口服系统进行靶向治疗提供了必要条件。
Absstract of: CN119464322A
本发明公开了yncJ基因在调控鼠伤寒沙门氏菌毒力中的应用，属于生物技术领域。本发明通过构建鼠伤寒沙门氏菌的yncJ基因缺失菌株对yncJ基因的功能进行研究，发现将yncJ基因缺失后，菌株在巨噬细胞内的增殖能力显著降低；通过感染小鼠实验发现，yncJ基因缺失菌株对小鼠的致死能力显著降低。而且，yncJ基因缺失菌株的常规生化特性和体外生长速度未见明显变化，因此，yncJ基因缺失菌株具有生产防治鼠伤寒沙门氏菌的减毒疫苗的应用前景。
Absstract of: CN119464158A
The invention belongs to the technical field of probiotics, and particularly relates to pediococcus acidilactici with acid resistance, bile salt resistance and antibacterial activity and application of the pediococcus acidilactici. The pediococcus acidilactici TR19 has the preservation number of CGMCC NO.31330 and is classified and named as pediococcus acidilactici according to microorganisms. The strain has good acid resistance and bile salt resistance, and can be used for preparing probiotics for preventing and treating bacteria. Meanwhile, the strain has a relatively strong bacteriostatic effect on escherichia coli, bacillus cereus, staphylococcus aureus and salmonella typhimurium, in addition, the strain has a relatively good degradation capability on nitrite and cholesterol, and the applicability is relatively strong.
Nº publicación: CN119433058A 14/02/2025
Applicant:
大连金石湾实验室大连工业大学
Absstract of: CN119433058A
本发明公开了一种基于纳米透镜高信噪比全息成像的数字化分析方法及系统，属于生化分析领域。本发明将微球纳米探针与高信噪比全息显微成像技术相结合，通过系列生化反应改变上清液/免疫复合物中微球信号探针的数量，磁分离后对上清液中PS微球纳米探针进行高信噪比全息成像；全息成像过程中利用声表面波‑叉指换能器驱动形成纳米透镜的高信噪比无透镜全息显微镜；利用轻量化的无监督学习目标检测算法获取全息图像中微球信号探针的数量，最终实现待测目标物的精准定量检测。实验结果表明，本发明有效地提升了检测灵敏度和效率，同时提高了检测准确率。
BOPI
Electronic site
